Close

BMO Capital Downgrades Pfizer (PFE) to Market Perform

Go back to BMO Capital Downgrades Pfizer (PFE) to Market Perform

Argus Downgrades Pfizer (PFE) to Hold

November 2, 2016 7:54 AM EDT

Argus downgraded Pfizer (NYSE: PFE) from Buy to Hold on a weaker outlook.

The analyst no longer expect PFE to achieve their former target price of $39 given recent pipeline setbacks, prospects for increased competition, and managements decision to shelve its business separation... More